Using light therapy to treat skin cancer from breast cancer
Official title: An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
Funded at Kintara Therapeutics, INC. · NIH-10877852 · Data updated 2026-11-12
This study is looking at a new way to treat skin cancer from breast cancer using a special light therapy that targets tumors while being gentle on healthy skin, and it's designed for patients who have stable cancer but are dealing with bothersome skin issues.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kintara Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Diego, UNITED STATES) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $745,259 |
| NIH project number | 5R44CA281615-02 |
| Project ID | NIH-10877852 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with symptomatic cutaneous lesions from metastatic breast cancer who have stable systemic disease.
✕Less likely to help
Patients with aggressive systemic disease or those who do not have cutaneous lesions may not benefit from this research.
What this research studies
This research investigates a new treatment for cutaneous metastatic breast cancer (CMBC) using a method called photodynamic therapy (PDT). In this approach, a special drug is injected into the body, which collects at tumor sites and is then activated by a laser to destroy cancer cells while sparing surrounding healthy tissue. The study aims to test a lower dosage of this drug to minimize side effects, which have been problematic in previous trials. By focusing on patients with stable systemic disease and symptomatic skin lesions, the research seeks to improve treatment outcomes and patient comfort.
Why it matters
Potential benefit: If successful, this research could provide a more effective and less harmful treatment option for patients suffering from cutaneous metastatic breast cancer.
How similar studies have gone: Previous studies using photodynamic therapy have shown promising results, indicating that this approach may be effective for treating similar conditions.
Where this research is happening
-
Kintara Therapeutics, INC.
San Diego, United States Active
Researchers
- Principal investigator: Brown, Dennis — Kintara Therapeutics, INC.
- Study coordinator: Brown, Dennis
Related research
Other NIH-funded projects on the same topics.
-
Understanding FGFR1-amplified breast cancer to overcome endocrine resistance
This project explores why a type of breast cancer with FGFR1 changes stops responding to hormone therapy and looks for new combination treatments that may help patients live longer.
-
Oral fulvestrant as the next standard of care for ER+ metastatic breast cancer
A new oral formulation of fulvestrant is being tested to help people with ER-positive metastatic breast cancer have a longer, better-tolerated response to treatment.
-
Fit2ThriveMB: A digital activity program to help people with metastatic breast cancer feel better and stay active
A digital, at-home physical activity program designed for people with metastatic breast cancer to improve quality of life and daily functioning.
-
Acupuncture to ease symptoms for people with metastatic breast cancer
A clinical trial will test whether weekly acupuncture for 12 weeks can reduce symptom burden for people with metastatic breast cancer who are on standard therapy.
-
Predicting end-of-life timing to guide better care for metastatic breast cancer
A clinician-facing project tests a breast cancer prognostic tool in everyday oncology care to help guide conversations and timely hospice referrals for patients nearing the end of life.
-
Combining antibody-drug conjugates with mechanism-based therapies to treat metastatic triple-negative breast cancer
A research team is testing new combination strategies that pair antibody-drug conjugates with other targeted treatments to better treat metastatic triple-negative breast cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.